Company: Tasly Pharmaceutical Group Company Limited
Bloomberg ticker: 600535 SH
Market cap: US$3,339m
Background: Tasly Pharmaceutical Group Company Limited focuses on research, development, manufacturing, and marketing of modern traditional Chinese medicine (TCM) and chemical drugs. Operating primarily in China with a growing international presence, its flagship product, Dantonic, is a cardiovascular TCM drug.
World Class Benchmarking of Tasly Pharmaceutical Group
(Click on image to enlarge)
- Profitable Growth rank of 6 was down compared to the prior period’s 5th rank
- This is below average performance compared to 380 large Health Care companies worldwide
- Profitability rank of 5 was better than its Growth rank of 8
- Profitability rank of 5 was down compared to the prior period’s 4th rank
- This is average performance compared to peers
- Growth rank of 8 was down compared to the prior period’s 6th rank
- This is below average performance compared to peers
More By This Author:
Stock Analysis: GFPT Public Company Limited
Stock Analysis: Tong Yang Industry
Stock Analysis: DigiPlus Interactive Corp.
Comments
Log in or sign up to join the conversation.